Autopsy report · NCT00091195

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Administratively complete.”

The sponsor’s own words in the registry.

Life of this trial

51 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
Interventions: romidepsin
Participants: 51
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.